Ginkgo Bioworks Holdings, Inc. Class A
As of Oct 22, 2026, Ginkgo Bioworks Holdings is in Stage 2, the uptrend phase, now in week 3 (since Oct 7, 2026). It closed at $9.71, 35.2% below its 52-week high and above its 200-day average, which is rising.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is DNA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
DNA among Biotechnology273rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …273 | DNA | Stage 2 · wk 3 | 35 | +13.2% |
Ginkgo Bioworks Holdings: quick answers
What stage is Ginkgo Bioworks Holdings in?
As of Oct 22, 2026, Ginkgo Bioworks Holdings (DNA) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 7, 2026 and is in week 3. What the four stages mean
Is Ginkgo Bioworks Holdings in an uptrend?
Yes. Ginkgo Bioworks Holdings is in a Stage 2 uptrend. It trades 13.9% above its 200-day average, which is rising.
How far is Ginkgo Bioworks Holdings from its 52-week high?
Ginkgo Bioworks Holdings closed at $9.71 on Oct 22, 2026, 35.2% below its 52-week high of $14.98. Its 52-week low is $5.48.
How has Ginkgo Bioworks Holdings performed over the past year?
As of Oct 22, 2026, Ginkgo Bioworks Holdings is down 26.0% over the past year and up 11.6% so far in 2026.
Which sector and industry is Ginkgo Bioworks Holdings in?
Ginkgo Bioworks Holdings is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.